TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20949850

Group type: EXPERIMENTAL
Intervention: 210 ms movement time
Number of subjects: 40

Group type: COMPARATOR
Intervention: 350 ms movement time
Number of subjects: 40
Study: 18444130

Group type: EXPERIMENTAL
Intervention: Soy protein isolate (SPI+)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Alcohol-washed soy protein (SPI-)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Milk protein (MPI)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Soy groups (SPI+ and SPI-)
Number of subjects: 58
Study: 16952205

Group type: EXPERIMENTAL
Intervention: 1.75 mg midazolam
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 5.25 mg midazolam
Number of subjects: 28
Study: 15561831

Group type: EXPERIMENTAL
Intervention: Levofloxacin at 750 mg once daily plus metronidazole at 500 mg every 8 hours
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Levofloxacin at 750 mg once daily plus metronidazole at 1,500 mg every 24 hours
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Levofloxacin at 750 mg once daily plus metronidazole at 1,000 mg every 24 hours
Number of subjects: 18
Study: 11451294

Group type: EXPERIMENTAL
Intervention: Early invasive strategy
Number of subjects: 2457

Group type: COMPARATOR
Intervention: Noninvasive strategy
Number of subjects: 2457
Study: 9084068

Group type: EXPERIMENTAL
Intervention: THA 25 mg
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: THA 50 mg
Number of subjects: 19
Study: 8273571

Group type: EXPERIMENTAL
Intervention: Azapropazone (APZ) 600 mg b.i.d.
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Indomethacin (IND) 50 mg t.i.d.
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Naproxen (NAP) 500 mg b.i.d.
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Piroxicam (PIR) 20 mg qq.d.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (C)
Number of subjects: 40
Study: 3315584

Group type: COMPARATOR
Intervention: Intracoronary streptokinase (20,000U bolus, then 2000 U/minute)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: APSAC (30U over 2 to 4 minutes)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: APSAC
Number of subjects: 93
Study: 30938014

Group type: EXPERIMENTAL
Intervention: CARE protocol training
Number of subjects: 49
Study: 27811072

Group type: EXPERIMENTAL
Intervention: Early adenotonsillectomy (n=182)
Number of subjects: 353

Group type: COMPARATOR
Intervention: Watchful waiting with supportive care (WWSC) (n=171)
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Surgical resolution of OSAS (based on apnoea-hypopnoea index)
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Spontaneous normalisation of apnoea-hypopnoea index
Number of subjects: 353
Study: 26220093

Group type: EXPERIMENTAL
Intervention: Small-incision phacotrab
Number of subjects: 49

Group type: COMPARATOR
Intervention: Phacoemulsification
Number of subjects: 49
Study: 24617278

Group type: EXPERIMENTAL
Intervention: Telephone support groups (15 groups of 5 or 6 caregivers), met 14 times over 1 year, 1-hour sessions including education, coping skills, and support
Number of subjects: 154

Group type: COMPARATOR
Intervention: Control group (print materials)
Number of subjects: 154
Study: 21392067

Group type: EXPERIMENTAL
Intervention: PF-734200 20 mg/day
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: PF-734200 30 mg/day
Number of subjects: 289

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 289
Study: 19139778

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Remifentanil
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 17223873

Group type: EXPERIMENTAL
Intervention: Topical methylaminolaevulinate (MAL) photodynamic therapy (PDT)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Topical 5% fluorouracil (5‐FU) cream
Number of subjects: 8
Study: 15346824

Group type: EXPERIMENTAL
Intervention: Close phototherapy (15 cm above the patient)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Remote phototherapy (30‐45 cm above patient)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group (incubator patients)
Number of subjects: 98
Study: 11394510

Group type: EXPERIMENTAL
Intervention: Midazolam 0.05 mg x kg(‐1) (PM; n = 13)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Saline placebo (PO; n = 11)
Number of subjects: 24
Study: 9766818

Group type: EXPERIMENTAL
Intervention: Transjugular intrahepatic portosystemic shunts (TIPS)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Paracentesis
Number of subjects: 5
Study: 7880512

Group type: EXPERIMENTAL
Intervention: Subarachnoid bupivacaine blockade (12.5 mg)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Intramuscular saline (control)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Intravenous midazolam (control)
Number of subjects: 53
Study: 3367388

Group type: EXPERIMENTAL
Intervention: 252Cf therapy
Number of subjects: 65

Group type: COMPARATOR
Intervention: 137Cs therapy
Number of subjects: 65
Study: 29333561

Group type: COMPARATOR
Intervention: Venetoclax (10-500 mg single doses and 30-600 mg multiple doses)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Venetoclax
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 27313280

Group type: EXPERIMENTAL
Intervention: TAVR with self-expanding bioprosthesis
Number of subjects: 747

Group type: COMPARATOR
Intervention: SAVR
Number of subjects: 747

Group type: EXPERIMENTAL
Intervention: TAVR
Number of subjects: 747
Study: 25088029

Group type: EXPERIMENTAL
Intervention: Polyphenol-enriched protein powder (PSPC) 40 g/day for 17 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (soy protein and colorings)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Polyphenol-enriched protein powder (PSPC)
Number of subjects: 0
Study: 22913893

Group type: EXPERIMENTAL
Intervention: Proactive intervention based on single-pill amlodipine/atorvastatin (SPAA) 5/10 to 10/20 mg
Number of subjects: 600

Group type: COMPARATOR
Intervention: Usual care (UC) based on investigators' best clinical judgment
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Proactive intervention based on SPAA
Number of subjects: 600

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 600
Study: 20825669

Group type: EXPERIMENTAL
Intervention: e-learning condition (three digital learning modules about alcohol, tobacco, and marijuana over three school years)
Number of subjects: 3784

Group type: EXPERIMENTAL
Intervention: integral condition (parental participation and monitoring in addition to the e-learning modules)
Number of subjects: 3784

Group type: COMPARATOR
Intervention: control condition (business as usual)
Number of subjects: 3784
Study: 18469568

Group type: EXPERIMENTAL
Intervention: Braced condition (neoprene knee sleeve)
Number of subjects: 64
Study: 16018384

Group type: EXPERIMENTAL
Intervention: TEP laparoscopic hernioplasty
Number of subjects: 60

Group type: COMPARATOR
Intervention: Bassni inguinal hernia repair
Number of subjects: 60
Study: 12852710

Group type: EXPERIMENTAL
Intervention: 10 g of PLT 3514 emulsion (0.75 g GLA + 0.5 g EPA)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: 20 g of PLT 3514 emulsion (1.5 g GLA + 1 g EPA)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: 100 g of PLT 3514 emulsion (7.5 g GLA + 5 g EPA)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo emulsion containing olive oil
Number of subjects: 47
Study: 10390662

Group type: EXPERIMENTAL
Intervention: Dimenhydrinate (62 mg IV after induction, repeated three times during 48 hours)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Placebo (saline, repeated three times during 48 hours)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Dimenhydrinate
Number of subjects: 133

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study: 8888596

Group type: EXPERIMENTAL
Intervention: Happy mood
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral mood
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sad mood
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Happy mood with secondary task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Happy mood with small script-inconsistent information
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sad mood with secondary task
Number of subjects: 0
Study: 1802054

Group type: EXPERIMENTAL
Intervention: Treatment regimes without bone grafting
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Treatment regimes including bone grafting at 10 years of age
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Group receiving bone grafts at 6 months after presurgical orthopaedics
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Group receiving bone grafts after the eruption of the incisors but before the eruption of the canines
Number of subjects: 85
Study: 6404440

Group type: EXPERIMENTAL
Intervention: Heat inactivated hepatitis B virus vaccine (3 micrograms HBsAg)
Number of subjects: 800

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Heat inactivated hepatitis B virus vaccine
Number of subjects: 800
Study: 31665039

Group type: EXPERIMENTAL
Intervention: Home-based cognitive rehabilitation (CR) program with psychological support for 8 weeks, consisting of three 45-minute sessions per week using PRESCO® software.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Psychological support only, addressing everyday cognitive-related difficulties and management of emotions.
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Home-based cognitive rehabilitation (CR) program with psychological support for 8 weeks.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Psychological support only.
Number of subjects: 40
Study: 29879143

Group type: EXPERIMENTAL
Intervention: Ipilimumab (0.1, 1, 3, or 5 mg/kg) administered every 28 days for 2 or 4 doses
Number of subjects: 24
Study: 27379733

Group type: EXPERIMENTAL
Intervention: DPP4 inhibitors
Number of subjects: 295

Group type: COMPARATOR
Intervention: Other antidiabetic therapies
Number of subjects: 295
Study: 25257633

Group type: EXPERIMENTAL
Intervention: TAVR
Number of subjects: 2211

Group type: COMPARATOR
Intervention: SAVR
Number of subjects: 2211
Study: 22661628

Group type: EXPERIMENTAL
Intervention: Isis (squeeze-handle mechanism)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Harmony (squeeze-handle mechanism)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Little Heart (cylindrical mechanism)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Evenflo (cylindrical mechanism)
Number of subjects: 0
Study: 20801248

Group type: EXPERIMENTAL
Intervention: Patients with LBP
Number of subjects: 48

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: All subjects
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Patients with LBP and Healthy controls
Number of subjects: 48
Study: 19098657

Group type: EXPERIMENTAL
Intervention: 1 g of Cefotaxime at the moment of gallbladder rupture, followed by 2 more doses at intervals of 8 hours in the immediate postoperative period
Number of subjects: 166

Group type: COMPARATOR
Intervention: No antibiotic treatment
Number of subjects: 166
Study: 16243241

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 12848773

Group type: EXPERIMENTAL
Intervention: 250 mg clarithromycin twice daily for 3 days
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intravenous digoxin with oral clarithromycin
Number of subjects: 12
Study: 10577448

Group type: EXPERIMENTAL
Intervention: Metoprolol succinate (CR/XL)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 8718540

Group type: COMPARATOR
Intervention: Conventional cartilaginous incisions
Number of subjects: 1164

Group type: EXPERIMENTAL
Intervention: Modification of cartilaginous incisions
Number of subjects: 1164

Group type: EXPERIMENTAL
Intervention: Both techniques of cartilaginous incision
Number of subjects: 1164
Study: 1868679

Group type: COMPARATOR
Intervention: Temazepam 20 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Temazepam 10 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Temazepam 5 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 7079903

Group type: EXPERIMENTAL
Intervention: Intramuscular injection of 15-(S)-15-methyl-PGF2 alpha
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Continuous intra-uterine extra-amniotic infusion of 15-(S)-15-methyl-PGF2 alpha
Number of subjects: 30
Study: 30789856

Group type: COMPARATOR
Intervention: Rabeprazole 10 mg
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Ilaprazole 5 mg
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Ilaprazole 10 mg
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 390
Study: 28434798

Group type: COMPARATOR
Intervention: Standard radiochemotherapy (stdRT) (70Gy/35 fractions)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Dose escalation (DE) (77Gy/35 fractions) to hypoxic volumes (HV)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Standard radiochemotherapy (stdRT)
Number of subjects: 25
Study: 27146475

Group type: EXPERIMENTAL
Intervention: Group Person‐Based Cognitive Therapy (PBCT) and Treatment As Usual (TAU)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Treatment As Usual (TAU)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Group Person‐Based Cognitive Therapy (PBCT)
Number of subjects: 108
Study: 24529582

Group type: EXPERIMENTAL
Intervention: Sertraline 25 mg/day for 1 week followed by 50 mg/day for 3 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Behavioral Therapy (BT) for 3 months
Number of subjects: 60
Study: 22807627

Group type: EXPERIMENTAL
Intervention: Tai chi
Number of subjects: 102
Study: 19179739

Group type: EXPERIMENTAL
Intervention: Cord serum screening test measuring total serum IgE, Der p1, Blo t5, and g IFN levels
Number of subjects: 100

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 100
Study: 17475584

Group type: EXPERIMENTAL
Intervention: Tamsulosin
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 15337334

Group type: EXPERIMENTAL
Intervention: Concordance Therapy
Number of subjects: 19

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 19
Study: 16779878

Group type: COMPARATOR
Intervention: No ointment
Number of subjects: 778

Group type: EXPERIMENTAL
Intervention: Paraffin ointment
Number of subjects: 778

Group type: EXPERIMENTAL
Intervention: Mupirocin ointment
Number of subjects: 778
Study: 10968910

Group type: EXPERIMENTAL
Intervention: Combined treatment with aspirin and heparin
Number of subjects: 0
Study: 8859914

Group type: EXPERIMENTAL
Intervention: Appointment group - given a follow-up appointment in the ED prior to discharge and written reminder
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Intense group - given a follow-up appointment in the ED prior to discharge, a written reminder, work excuse, child care, transportation assistance, mailed reminders, and telephone reminders
Number of subjects: 253

Group type: COMPARATOR
Intervention: Control group - told to call the clinic for follow-up appointments
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Intense group - successful telephone contact
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Families left to make their own follow-up appointments
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 253
Study: 1463530

Group type: EXPERIMENTAL
Intervention: Enalapril (2.5 to 20 mg per day)
Number of subjects: 4228

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4228
Study: 6733393

Group type: EXPERIMENTAL
Intervention: d-amphetamine 7.5 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: d-amphetamine 12.5 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 30742838

Group type: EXPERIMENTAL
Intervention: Caffeine (CAF) ingestion
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (PLA) ingestion
Number of subjects: 12
Study: 29576535

Group type: EXPERIMENTAL
Intervention: Caloric Restriction (CR)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control
Number of subjects: 53
Study: 26135372

Group type: EXPERIMENTAL
Intervention: Resistive underwater exercises and interferential current therapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Traditional physical therapy program (Control)
Number of subjects: 30
Study: 24246718

Group type: EXPERIMENTAL
Intervention: Active reading condition
Number of subjects: 638

Group type: EXPERIMENTAL
Intervention: Passive reading condition
Number of subjects: 638

Group type: EXPERIMENTAL
Intervention: Intervention group (Study 2)
Number of subjects: 638

Group type: COMPARATOR
Intervention: Control group (Study 2)
Number of subjects: 638
Study: 21415232

Group type: EXPERIMENTAL
Intervention: Sexual health promotion messages via SMS and email (n=507)
Number of subjects: 994

Group type: COMPARATOR
Intervention: Control group (n=487)
Number of subjects: 994
Study: 22009840

Group type: EXPERIMENTAL
Intervention: Surgical treatment through the paravertebral muscle approach
Number of subjects: 62

Group type: COMPARATOR
Intervention: Traditional surgical procedure
Number of subjects: 62
Study: 17156263

Group type: EXPERIMENTAL
Intervention: Almotriptan 12.5 mg
Number of subjects: 1062

Group type: COMPARATOR
Intervention: Zolmitriptan 2.5 mg
Number of subjects: 1062
Study: 15830922

Group type: EXPERIMENTAL
Intervention: Synthetic lycopene
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lyc-o-Mato
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lyc-o-Guard-Drink
Number of subjects: 0
Study: 11976195

Group type: EXPERIMENTAL
Intervention: Diet adequate in vitamin C
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diet deficient in vitamin C
Number of subjects: 0
Study: 9473971

Group type: EXPERIMENTAL
Intervention: 12-week psychoeducational intervention (2 h/week)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: 12-week education intervention (1 h/week)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 78
Study: 7635995

Group type: EXPERIMENTAL
Intervention: Buspirone (up to 60 mg/day)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study: 31177248

Group type: EXPERIMENTAL
Intervention: rTMS with AO
Number of subjects: 22

Group type: COMPARATOR
Intervention: rTMS alone
Number of subjects: 22
Study: 28371571

Group type: EXPERIMENTAL
Intervention: True acupuncture
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 50
Study: 25399306

Group type: EXPERIMENTAL
Intervention: Jinlongshe Granule (JLSG)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 23194834

Group type: EXPERIMENTAL
Intervention: Haloperidol (2 mg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 21530058

Group type: EXPERIMENTAL
Intervention: Metformin (1700‐3000 mg/day)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Control group (normal pregnant women)
Number of subjects: 208
Study: 19117084

Group type: EXPERIMENTAL
Intervention: Barley starch syrup
Number of subjects: 15

Group type: COMPARATOR
Intervention: Cereals (wheat, barley, rye, oats)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Skin-prick tests (SPT)
Number of subjects: 15
Study: 16781068

Group type: EXPERIMENTAL
Intervention: Acupuncture (up to 15 sessions over three months)
Number of subjects: 1880

Group type: COMPARATOR
Intervention: Control (routine care alone)
Number of subjects: 1880
Study: 15291866

Group type: COMPARATOR
Intervention: Ileal conduit diversion (group 1)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Modified S-pouch neobladder (group 2)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Healthy subjects (control group 3)
Number of subjects: 162
Study: 11532741

Group type: EXPERIMENTAL
Intervention: Vitamin B(6)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 9421774

Group type: EXPERIMENTAL
Intervention: 48 h change of infusion systems
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 96 h change of infusion systems
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: In-line infusion filters
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Cell-bound endotoxin
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Free endotoxin
Number of subjects: 19
Study: 8214738

Group type: EXPERIMENTAL
Intervention: Endotracheal lidocaine administration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Deep endobronchial lidocaine administration
Number of subjects: 0
Study: 3307601

Group type: EXPERIMENTAL
Intervention: DDP (Cisplatinum) 100 mg/m2 administered on day 1
Number of subjects: 136

Group type: COMPARATOR
Intervention: DDP-Etoposide (DDP 100 mg/m2 on day 4 and Etoposide 100 mg/m2 per os on days 1 to 5)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Both groups (DDP and DDP-Etoposide)
Number of subjects: 136
Study: 31743039

Group type: EXPERIMENTAL
Intervention: Immobilized leg (7 days of unilateral leg immobilization)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Immobilized leg (2 days of immobilization)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Immobilized leg (7 days of immobilization)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control leg (non-immobilized leg)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Immobilized leg
Number of subjects: 13
Study: 29577247

Group type: EXPERIMENTAL
Intervention: Topical application of a water-in-oil emulsion with pH 4
Number of subjects: 0

Group type: COMPARATOR
Intervention: Topical application of a water-in-oil emulsion with pH 5.8
Number of subjects: 0
Study: 29278471

Group type: EXPERIMENTAL
Intervention: Tonglin Powder
Number of subjects: 100

Group type: COMPARATOR
Intervention: Terazosin
Number of subjects: 100
Study: 25158949

Group type: EXPERIMENTAL
Intervention: Self-etching fluoride-releasing primer (Transbond™ Plus; group C)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Traditional acid-etching with 35% phosphoric acid and Transbond™ XT (group D)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Self-etching non-fluoride primer (iBond™ Gluma® Inside; group B)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Untreated control sample (group A)
Number of subjects: 15